Catalog No.
DHD12601
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
Fab-G1-kappa
Clonality
Monoclonal
Target
Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A
Concentration
1.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein L purified from cell culture supernatant.
Accession
P15692
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Fab-12 variant Y0317, RhuFab, CAS: 347396-82-1
Clone ID
Ranibizumab
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial, PMID: 30043039
Ranibizumab for myopic choroidal neovascularization, PMID: 33003962
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T, PMID: 28837425
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial, PMID: 31522845
Ranibizumab: A Review in Retinopathy of Prematurity, PMID: 33447937
The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial, PMID: 30946888
Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis, PMID: 30071180
Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study, PMID: 32492069
The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective, PMID: 29772018
Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy, PMID: 31999300
Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison, PMID: 32222903
Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis, PMID: 30464394
Ranibizumab for age-related macular degeneration, PMID: 22309606
Ranibizumab and digital ischemia, PMID: 29425544
Assessing the role of ranibizumab in improving the outcome of glaucoma filtering surgery and neovascular glaucoma, PMID: 29781319
Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration, PMID: 26076760
Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration, PMID: 29476754
Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial, PMID: 33211076
Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial, PMID: 32855889
[Ranibizumab and aflibercept for diabetic macular edema-retrospective study with real-life data after 12 months], PMID: 31705192
Intravitreal ranibizumab and dexamethasone implant injections as primary treatment of diabetic macular edema: simultaneously double protocol, PMID: 32398852
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies, PMID: 31728825
Intraocular Pharmacokinetics of 10-fold Intravitreal Ranibizumab Injection Dose in Rabbits, PMID: 32818095
Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration, PMID: 32962487
Ranibizumab for the treatment of wet AMD: a summary of real-world studies, PMID: 26634711
Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity, PMID: 30995663
Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study, PMID: 33378369
Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab, PMID: 26501149
Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: A systematic review and meta-analysis, PMID: 29753123
Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema, PMID: 32908935
Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges, PMID: 28484955
Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study, PMID: 31961888
Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK, PMID: 30726549
Intravitreal ranibizumab reduced ocular blood flow and aqueous cytokine levels and improved retinal morphology in patients with diabetic macular edema, PMID: 33303870
Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity, PMID: 31124535
Ranibizumab for Macular Edema Secondary to Central and Branch Retinal Vein Occlusion in Patients Younger Than 50 Years of Age, PMID: 32685489
Aflibercept for neovascular age-related macular degeneration, PMID: 26857947
Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression, PMID: 31165769
Switching from ranibizumab and aflibercept to bevacizumab therapy in neovascular age-related macular degeneration patients, PMID: 32375502
Cost-Minimization Analysis of Ranibizumab Versus Aflibercept for Treating Saudi Patients With Visual Impairment Owing to Age-Related Macular Degeneration or Diabetic Macular Edema, PMID: 32247191
Biomechanical properties of the cornea following intravitreal ranibizumab injection, PMID: 33165643
Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy, PMID: 31324161
Cardiovascular risk in patients receiving ranibizumab for exudative age-related macular degeneration: a nationwide self-controlled case-series study, PMID: 32522792
Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context, PMID: 29486762
Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice, PMID: 31644594
Ranibizumab in macular oedema secondary to branch retinal vein occlusion - 24 months of treatment, PMID: 32397721
Use of Bevacizumab and Ranibizumab for Wet Age-Related Macular Degeneration: Influence of CATT Results and Introduction of Aflibercept, PMID: 31100217
Ranibizumab for the treatment of choroidal neovascularization due to cause other than age related macular degeneration, PMID: 31779462
Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study, PMID: 32555630
Effect of intravitreal ranibizumab pretreatment on vitrectomy in young patients with proliferative diabetic retinopathy, PMID: 32005066
For research use only. Not for human or drug use.
